Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NTQ2494 in Relapsed/Refractory AML
NCT06049667Phase 1Recruiting
- Sponsor
- Nanjing Chia-Tai Tianqing Pharmaceutical
- Start
- Aug 2023
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NTQ2494 in acute myeloid leukemia (AML), sponsored by Nanjing Chia-Tai Tianqing Pharmaceutical. Primary endpoints: Maximum Tolerance Dose at 30 days and Dose Limiting Toxicity at 30 days. Started Aug 2023; status: recruiting.
02
Drugs
NTQ2494
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06049667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06049667.